38 Biggest Movers From Yesterday

Gainers

• Helios and Matheson Analytics Inc. HMNY jumped 31.15 percent to close at $4.21 on Monday after climbing 6.29 percent on Friday.
• Intelsat S.A. I shares gained 18.79 percent to close at $8.41 after the company disclosed that its wholly-owned subsidiary, Intelsat General, is a part of team of companies awarded new task order by the FAA to develop and operate satellite payload.
• Aptevo Therapeutics Inc. APVO climbed 17.99 percent to close at $4.46 as the company disclosed that APVO436 showed T-Cell activation with minimal cytokine release.
• Eldorado Resorts, Inc. ERI shares surged 16.25 percent to close at $41.50 on Monday after the company announced plans to buy Tropicana Entertainment for $1.85 billion in cash. MGM Resorts International MGM reported the sale of Grand Victoria Casino in Elgin, Illinois to Eldorado Resorts for $327.5 million in cash.
• Carvana Co. CVNA shares climbed 15.51 percent to close at $27.03.
• FTD Companies, Inc. FTD gained 14.47 percent to close at $6.25.
• Apellis Pharmaceuticals, Inc. APLS shares rose 12.23 percent to close at $30.00 on Monday.
• Turtle Beach Corporation HEAR shares gained 11.76 percent to close at $4.37.
• Viveve Medical, Inc. VIVE shares climbed 11.63 percent to close at $3.36.
• Sorrento Therapeutics, Inc. SRNE shares rose 11.11 percent to close at $6.50.
• tronc, Inc. TRNC shares rose 10.79 percent to close at $19.00 on Monday.
• Energous Corporation WATT shares surged 9.96 percent to close at $19.99.
• REGENXBIO Inc. RGNX shares gained 9.83 percent to close at $38.00.
• Bovie Medical Corporation BVX rose 8.49 percent to close at $3.45.
• Aptose Biosciences Inc. APTO rose 8.21 percent to close at $3.56. Aptose announced the presentation of new preclinical data on CG’806 Pan-FLT3/ Pan-BTK inhibitor at the 2018 AACR Annual Meeting.
• BlueLinx Holdings Inc. BXC shares gained 7.6 percent to close at $38.38. BlueLinx disclosed that it has completed its announced acquisition of Cedar Creek.
• Ossen Innovation Co., Ltd. OSN shares gained 7.23 percent to close at $2.52 on Monday.
• Alkermes plc ALKS rose 4.47 percent to close at $44.43 after the company reported the FDA acceptance for review of the NDA for ALKS 5461 for the adjunctive treatment of major depressive disorder.

Losers

• Celldex Therapeutics, Inc. CLDX shares tumbled 64.61 percent to close at $0.761 on Monday after the company disclosed that its METRIC study in metastatic triple-negative breast cancer did not meet primary endpoint.
• Acacia Communications, Inc. ACIA shares fell 35.97 percent to close at $25.63. Optical stocks were trading under notable selling pressure Monday morning in reaction to the U.S. government's move to ban American companies from selling their equipment to China's ZTE Corp. The company said in a 10-K filing dated Feb. 22 it generates most of its revenue from a limited number of customers. Among its biggest customers is ZTE, which accounted for 30 percent of its entire revenue in 2017.
• Apricus Biosciences, Inc. APRI dipped 35.38 percent to close at $0.2714. The urology and rheumatology focused biopharmaceutical company said the FDA recommended the company reformulates its Vitaros therapy. Specifically, the FDA is recommending the company "develop a new Vitaros formulation that reduces the concentration of DDAIP.HCl from 2.5% to 0.5% in order to address the tumor promotion and partner transference safety concerns."
• Leap Therapeutics, Inc. LPTX shares fell 23.1 percent to close at $7.49. Leap Therapeutics presented nonclinical and clinical data on DKN-01 at the AACR 2018 Annual Meeting.
• CYANOTECH CORP CYAN fell 16.83 percent to close at $4.20.
• Oclaro, Inc. OCLR dropped 15.18 percent to close at $7.99. Optical stocks were trading under notable selling pressure Monday morning in reaction to the U.S. government's move to ban American companies from selling their equipment to China's ZTE Corp. Oclaro shares fell as ZTE accounted for 18 percent of its 2017 revenue.
• VirnetX Holding Corp VHC shares slipped 13.33 percent to close at $3.25.
• Future FinTech Group Inc. FTFT shares fell 13.2 percent to $2.17.
• Blueprint Medicines Corporation BPMC dropped 12.64 percent to close at $86.46 after the company disclosed proof-of-concept data from the ongoing Phase 1 ARROW clinical trial of BLU-667 in patients with RET-altered solid tumors.
• Agenus Inc. AGEN shares fell 11.61 percent to close at $4.11.
• Foundation Medicine, Inc. FMI shares dropped 11.6 percent to close at $70.90 on Monday.
• Zafgen, Inc. ZFGN shares declined 10.4 percent to close at $6.89.
• Clovis Oncology, Inc. CLVS fell 10.27 percent to close at $54.41 after the company disclosed proposed offerings of convertible senior notes and common stock.
• SemiLEDs Corporation LEDS shares slipped 10.26 percent to close at $3.50.
• Fabrinet FN shares dropped 9.81 percent to close at $30.17.
• NewLink Genetics Corporation NLNK fell 7.72 percent to close at $4.12 after the company reported initial Phase 1 data with indoximod plus radiation and chemotherapy for pediatric patients with diffuse intrinsic pontine glioma at the American Association for Cancer Research (AACR) 2018 Annual Meeting.
• Cerecor Inc. CERC fell 7.57 percent to close at $3.42.
• National Oilwell Varco, Inc. NOV shares declined 7.18 percent to close at $37.98 after the company issued weak sales forecast for the first quarter.
• Nektar Therapeutics NKTR shares fell 7 percent to close at $93.47. Nektar Therapeutics presented new preclinical data for its immuno-oncology programs at the AACR.
• WPP plc WPP fell 4.7 percent to close at $80.56 after the company disclosed that Sir Martin Sorrell has stepped down as CEO of the company.